Back to discover

Protein / target

Interleukin-10 receptor subunit beta

Encoded byIL10RBQ08334Homo sapiensSwiss-Prot
UniProt: Q08334Ensembl: ENSG00000243646HGNC: HGNC:5965NCBI Gene: 3588
Clinical-stage
Therapeutic maturity
3
Clinical candidates
7
Clinical trials
Antibody-tractable
Druggability
GO CC high conf

Protein at a glance

Biological role

Interleukin-10 receptor

Strongest disease association

COVID-19

Via encoding gene IL10RB · Genetic evidence · score 0.76

Therapeutic position

Clinically advancing target

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Shared cell surface receptor required for the activation of five class 2 cytokines: IL10, IL22, IL26, IL28, and IFNL1.

View complete UniProt function annotation

Shared cell surface receptor required for the activation of five class 2 cytokines: IL10, IL22, IL26, IL28, and IFNL1. The IFNLR1/IL10RB dimer is a receptor for the cytokine ligands IFNL2 and IFNL3 and mediates their antiviral activity. The ligand/receptor complex stimulate the activation of the JAK/STAT signaling pathway leading to the expression of IFN-stimulated genes (ISG), which contribute to the antiviral state

Subcellular location

Membrane
Domains and Gene Ontology detail (23)

Domains & features

Fibronectin type-III 1Fibronectin type-III 2

Gene Ontology

  • Cinterleukin-28 receptor complex
  • Cmembrane
  • Cplasma membrane
  • Fcoreceptor activity
  • Finterleukin-10 receptor activity
  • Fsignaling receptor activity
  • Pacute-phase response
  • Pcell surface receptor signaling pathway via JAK-STAT
  • Pcellular response to virus
  • Pcytokine-mediated signaling pathway
  • Pdefense response to virus
  • Pimmune response

325 aa · 37 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalGOImmune signallingUniProt · GO
View supporting evidence

Cell proliferation & survival

  • ·positive regulation of cell population proliferation

Immune signalling

  • ·Shared cell surface receptor required for the activation of five class 2 cytokines: IL10…
  • ·interleukin-28 receptor complex
  • ·interleukin-10 receptor activity
  • ·cytokine-mediated signaling pathway

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

Pegilodecakin
Phase 3Agonist

IL-10 receptor agonist

Acts on a complex — shared with IL10RA · 1 of 2 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene IL10RB

Gene-level evidence surfaced through the gene IL10RBthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

COVID-19
0.86Well supported

Genetic evidence dominant · Open Targets 0.54

Inflammatory Bowel Diseases
0.54Moderately supported

Genetic literature evidence dominant · Open Targets 0.39

Colitis, Ulcerative
0.49Limited support

Genetic literature evidence dominant · Open Targets 0.37

Hepatitis C, Chronic
0.46Limited support

Clinical evidence dominant · Open Targets 0.37

Carcinoma, Pancreatic Ductal
0.33Limited support

Clinical evidence dominant · Open Targets 0.26

View evidence synthesis (5)
COVID-19Well supported
0.86
agreement 0.76–0.97
Genetic61%Clinical30%Literature9%

Open Targets aggregate 0.54 · 3 independent evidence families

Inflammatory Bowel DiseasesModerately supported
0.54
agreement 0.38–0.69
Genetic literature84%Literature17%

Open Targets aggregate 0.39 · 2 independent evidence families

Colitis, UlcerativeLimited support
0.49
agreement 0.34–0.64
Genetic literature99%Literature1%

Open Targets aggregate 0.37 · 2 independent evidence families

Hepatitis C, ChronicLimited support
0.46
agreement 0.30–0.61
Clinical99%Literature1%

Open Targets aggregate 0.37 · 2 independent evidence families

Carcinoma, Pancreatic DuctalLimited support
0.33
agreement 0.17–0.48
Clinical97%Literature3%

Open Targets aggregate 0.26 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
COVID-190.54
Inflammatory Bowel Diseases0.39
Colitis, Ulcerative0.37
Hepatitis C, Chronic0.37
Carcinoma, Pancreatic Ductal0.26
Pancreatic adenocarcinoma0.26

Drug development

3 compounds recorded · 3 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph: these count different sets and are not a subset relation.

View all recorded compounds (3)
EFLEPEDOCOKIN ALFAPhase 2
PEGINTERFERON LAMBDA-1APhase 3
PEGILODECAKINPhase 3

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Antibodies — Emerging

Feasibility evidence (go cc high conf and uniprot sigp or tmhmm) — no clinical-stage drug of this modality recorded.

Other modalities — Strong

Advanced Clinical support this modality.

View underlying tractability evidence (3)
AB · GO CC high confAB · UniProt SigP or TMHMMOC · Advanced Clinical

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

7

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing RegimenPHASE3

COMPLETED · via Pegilodecakin · NCT02923921

A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1PHASE2

TERMINATED · via Pegilodecakin · NCT03382912

A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)PHASE2

TERMINATED · via Pegilodecakin · NCT03382899

An Open Label, Randomized, Single Dose, 2-Way Crossover Study to Evaluate the Pharmacokinetics of Pre-filled Syringe Versus Vial Formulations of AM0010 in Healthy Adult SubjectsPHASE1

COMPLETED · via Pegilodecakin · NCT04194892

View all trials (3)
An Open Label, Randomized, Single Dose, 3-Way Crossover Study to Evaluate the Pharmacokinetics of Different Dose Levels and Dose Formulations of AM0010 in Healthy Adult SubjectsPHASE1

COMPLETED · via Pegilodecakin · NCT03381547

A Phase 1 Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of AM0010 in Healthy Adult SubjectsPHASE1

COMPLETED · via Pegilodecakin · NCT03267732

A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid TumorsPHASE1

COMPLETED · via Pegilodecakin · NCT02009449

ClinicalTrials.gov via the drug-target graph.